

INFORMATION DISCLOSURE CITATION	Docket No. 0701.123A	Serial No.
	Applicant: Yelle et al.	
	Filing Date:	Group:

97-104654
10/19/01

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
W	AA	4,628,098	1986	Nohara et al.	546	271	
W	AB	4,689,333	1987	Nohara et al.	514	338	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	Date	Country	Class	Subclass	Translation	
						Yes	No

Other Documents (including Author, Title, Date, pertinent public. etc.)

W	CA	Katsuki et al. "Determination of R(+) and S(-)-Lansoprazole Using Chiral Stationary-Phase Liquid Chromatography..." <u>Pharm. Res.</u> 13, 611-615 (1996)
W	CB	Pearce et al. "Identification of the Human P450 Enzymes Involved in Lansoprazole Metabolism" <u>J. Pharm. Exp. Ther.</u> 277, 805-816 (1996)
W	CC	Fort et al. "Mechanism for Species-Specific Induction of Leydig Cell Tumors in Rats by Lansoprazole" <u>Fund. Appl. Toxicol.</u> 26, 191-202 (1995)
W	CD	Andersson "Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors" <u>Clin. Pharmacokinet</u> 1, 9-28 (1996)
W	CE	Chem. Abstract 115:21996
W	CF	Katsuki et al. "Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects" <u>Eur. J. Clin. Pharmacol.</u> 52, 391-396 (1997)
W	CG	Nagata et al. "Growth Inhibition of <i>Ureaplasma Urealyticum</i> by the Proton Pump Inhibitor Lansoprazole: Direct Attribution to Inhibition..." <u>Anti. Agents Chemo.</u> 39, 2187-2192 (1995)
W	CH	Sohn et al. "Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status" <u>Clin. Pharm. Ther.</u> 61, 574-582 (1997)
W	CI	Pichard et al. "Oxidative Metabolism of Lansoprazole by Human Liver Cytochromes P450" <u>Mol. Pharm.</u> 47, 410-418 (1995)
W	CJ	Aoki et al. "High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine" <u>J. Chromatography</u> 571, 283-290 (1991)
Examiner	R Cook	Date Considered 7/29/02